Literature DB >> 16266983

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

Christian H Brandts1, Bülent Sargin, Miriam Rode, Christoph Biermann, Beate Lindtner, Joachim Schwäble, Horst Buerger, Carsten Müller-Tidow, Chunaram Choudhary, Martin McMahon, Wolfgang E Berdel, Hubert Serve.   

Abstract

Up to 30% of patients with acute myeloid leukemia (AML) harbor internal tandem duplications (ITD) within the FLT3 gene, encoding a receptor tyrosine kinase. These mutations induce constitutive tyrosine kinase activity in the absence of the natural Flt3 ligand and confer growth factor independence, increased proliferation, and survival to myeloid precursor cells. The signaling pathways and downstream nuclear targets mediating leukemic transformation are only partly identified. Here, we show that the presence of Flt3-ITD constitutively activates Akt (PKB), a key serine-threonine kinase within the phosphatidylinositol 3-kinase pathway. Constitutive activation of Akt phosphorylated and inhibited the transcription factor Foxo3a. Restored Foxo3a activity reversed Flt3-ITD-mediated growth properties and dominant-negative Akt prevented Flt3-ITD-mediated cytokine independence. Conditional Akt activation targeted to the cell membrane induced cytokine-independent survival, cell cycle progression, and proliferation. Importantly, Akt activation was sufficient to cause in vitro transformation of 32D myeloid progenitor cells and in vivo promoted the development of a leukemia-like myeloid disease. Akt phosphorylation was found in myeloid blasts of 86% of AML patients, suggesting an important role in leukemogenesis. In summary, Akt is necessary for increased survival, proliferation, and leukemic transformation by Flt3-ITD, possibly by inactivation of Foxo transcription factors. These findings indicate that Akt and Foxo transcription factors are attractive targets for therapeutic intervention in AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266983     DOI: 10.1158/0008-5472.CAN-05-0422

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  90 in total

1.  AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.

Authors:  Xinping Yang; Suiyang Liu; Surender Kharbanda; Richard M Stone
Journal:  Leuk Res       Date:  2011-12-03       Impact factor: 3.156

2.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

Review 3.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

4.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

5.  Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?

Authors:  Sabine Kayser; Mark J Levis
Journal:  Int J Hematol Oncol       Date:  2017-02-24

6.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

7.  Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Authors:  Brittany Knick Ragon; Olatoyosi Odenike; Maria R Baer; Wendy Stock; Gautam Borthakur; Keyur Patel; Lina Han; Helen Chen; Helen Ma; Loren Joseph; Yang Zhao; Keith Baggerly; Marina Konopleva; Nitin Jain
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-26

Review 8.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

9.  NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Authors:  D Gerloff; R Grundler; A A Wurm; D Bräuer-Hartmann; C Katzerke; J-U Hartmann; V Madan; C Müller-Tidow; J Duyster; D G Tenen; D Niederwieser; G Behre
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

10.  Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Authors:  Ivana Gojo; Alexander Perl; Selina Luger; Maria R Baer; Kelly J Norsworthy; Kenneth S Bauer; Michael Tidwell; Stephanie Fleckinger; Martin Carroll; Edward A Sausville
Journal:  Invest New Drugs       Date:  2013-02-27       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.